An FDA advisory panel voted against approval of the appetite-suppressing, anti-obesity drug lorcaserin in September this year. Do the findings of a recent, randomized trial of lorcaserin provide clues to the decision?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Smith, S. R. et al. Multicenter, placebo-controlled trial of Lorcaserin for weight management. N. Engl. J. Med. 363, 245–256 (2010).
Warren, C. & Cooper, P. J. Psychological effects of dieting. Br. J. Clin. Psychol. 27, 269–270 (1988).
Blundell, J. E. et al. Overconsumption and obesity: peptides and susceptibility to weight gain. Regul. Pept. 149, 32–38 (2008).
Blundell, J. E. & Finlayson, G. Is susceptibility to weight gain characterized by homeostatic or hedonic risk factors for overconsumption? Physiol. Behav. 82, 21–25 (2004).
Halford, J. C. G., Boyland, E. J., Blundell, J. E., Kirkham, T. C. & Harrold, J. A. Pharmacological management of appetite expression in obesity. Nat. Rev. Endocrinol. 6, 225–269 (2010).
Elfhag, K., Finer, N. & Rössner, S. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. Diabetes Obes. Metab. 10, 498–505 (2008).
Halford, J. C., Harrold, J. A., Boyland, E. J., Lawton, C. L. & Blundell, J. E. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67, 27–55 (2007).
Li, Z. et al. Meta-analysis: pharmacologic treatments of obesity. Ann. Intern. Med. 142, 532–546 (2005).
Elfhag, K. & Rössner, S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. Obes. Rev. 6, 67–85 (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares associations with the following companies: Coca-Cola (grant/research support), Danone (consultant), GlaxoSmithKline (speakers bureau), Natures Remedies (grant/research support), Prosidion OSI (consultant).
Rights and permissions
About this article
Cite this article
Halford, J. Lorcaserin—not a new weapon in the battle with appetite. Nat Rev Endocrinol 6, 663–664 (2010). https://doi.org/10.1038/nrendo.2010.193
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.193
